Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) was the recipient of a significant drop in short interest in the month of July. As of July 31st, there was short interest totaling 15,100 shares, adropof33.5% from the July 15th total of 22,700 shares. Based on an average daily trading volume, of 45,300 shares, the short-interest ratio is presently 0.3 days. Based on an average daily trading volume, of 45,300 shares, the short-interest ratio is presently 0.3 days.
Analysts Set New Price Targets
Separately, Morgan Stanley restated an "overweight" rating on shares of Fresenius SE & Co. in a report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy".
Check Out Our Latest Research Report on FSNUY
Fresenius SE & Co. Trading Up 1.6%
Shares of FSNUY traded up $0.22 during midday trading on Friday, hitting $14.09. 128,805 shares of the stock traded hands, compared to its average volume of 49,099. Fresenius SE & Co. has a 1-year low of $8.4780 and a 1-year high of $14.20. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 1.43. The business's 50 day moving average price is $12.50 and its two-hundred day moving average price is $11.59.
Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.02. Fresenius SE & Co. had a net margin of 5.09% and a return on equity of 9.33%. The company had revenue of $6.48 billion during the quarter, compared to the consensus estimate of $5.83 billion. Analysts forecast that Fresenius SE & Co. will post 0.79 earnings per share for the current year.
About Fresenius SE & Co.
(
Get Free Report)
Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Featured Stories
Before you consider Fresenius SE & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius SE & Co. wasn't on the list.
While Fresenius SE & Co. currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.